An IPO Alternative: Life Sciences Reverse Merger

Many companies are seeking alternatives to the traditional IPO, and considering merging into a SPAC, or a reverse merger. For life sciences companies, reverse merger transactions have become a popular alternative approach to going public. Merging into a public life sciences company that has cash on hand and has experienced a failed clinical program raises a number of legal considerations. During this session, we will discuss:

• How this differs from a reverse merger into a shell;
• Structuring alternatives;
• Documentation, process and timeline;
• Addressing board and employee matters;
• Anticipating litigation; and
• Concurrent or subsequent financing opportunities.

CLE is not available when viewing a recording of this program. In order to receive credit you must have attended the live webinar program.